[Market Focus] Genomictree Rises on Confirmation of Expert Committee Meeting for EarlyTect-B Approval by MFDS
![[Market Focus] Genomictree Rises on Confirmation of Expert Committee Meeting for EarlyTect-B Approval by MFDS](http://www.asiae.co.kr/news/img_view.htm?img=2025110409131793207_1762215197.jpg)
Genomictree shares are showing strong performance. This appears to be influenced by news that the Ministry of Food and Drug Safety has finalized plans to hold an expert committee meeting on November 6 regarding the manufacturing approval review for Genomictree's bladder cancer in vitro diagnostic test, 'EarlyTect-B'.
As of 1:56 p.m. on November 4, Genomictree is trading at 25,200 won, up 13.77% from the previous day.
A Genomictree representative stated, "The confirmation of this schedule is the result of the Ministry of Food and Drug Safety actively working to expedite the review process by managing this case as a 'top-priority civil petition.' Despite initial difficulties in coordinating the schedule, the meeting date was set quickly."
Hot Picks Today
"Should Get at Least 45 Million Won Salary" "Can't Give Up on Large Companies"... Young People Say There Are No Places to Apply
- Unemployment Benefits to Drop from 1.98 Million to 1.76 Million Won per Month...Employment Insurance Premium Rate to Rise from 1.8% to 2%
- Packed Crowds with “It’s So Cheap!”... Japan Travel by UK Millennials & Gen Z Surges 25% in a Year
- "Only One Restroom Break per Semester During Class"…Controversy Over Chinese High School Regulations
- When "Cutting Down Reserved Tents" Brings Relief: Local Governments Take Action Against Escalating 'Reserved Tent' Problem
The company added, "The Ministry of Food and Drug Safety has already completed most of the key document reviews, and with this upcoming expert committee meeting, we expect the approval review process to enter its final stage."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
